In addition, USP13 was found to be enriched in the hypoxia response via HIF activation, suggesting that targeting USP13 may suppress hypoxia and thereby promote immune infiltration and the response to immunotherapy in prostate cancer [34]. The gene discussed is USP13; the disease is prostate cancer.